Skip to content

Study · Randomized controlled trial · n = 52 · 2015

8 results

[Prevention Effect of Thymosin-alpha1 Aganist Early Ventilator-associated Pneumonia in Patients with Mechanical Ventilation].

Zhang SS, Li K, Wang YH, Ye BN, Pan Y, Shi XQ

Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition1 Nov 2015Cited by 1 (Europe PMC)

PMID26867337 (opens in a new tab)PepBankPUB-26867337
Publisher pageAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with mechanical ventilation, VAP incidence was lower with thymosin than with routine therapy, but the difference was not significant.

    In plain wordsIn ventilated patients, pneumonia was less common with thymosin alpha‑1 than with routine care, but the difference was not significant.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeIncidence of early ventilator-associated pneumonia
    Study

    n = 52

    Comparator
    Routine therapy
    Outcome group
    Infection and antimicrobial activity · Respiratory
    Studied dose
    1.6 mg once daily · subcutaneous injection · 7 daysAs given in this study (human).

    Source sentences

    Summary
    The incidence of VAP in thymosin therapy group was lower than that in routine therapy group, but it was not significant difference (P>0.05).
    2 context sentences
    Summary · context
    Fifty two patients with expectancy of mechanical ventilation over 48 h were divided into routine therapy group (n=26) and thymosin therapy group (n= 26) in random.
    Summary · context
    The patients in routine therapy group were given intensive care unit (ICU) conventional treatment, and the patients in thymosin therapy group were given thymosin treatment additionally (1.6 mg subcutaneous injection, qd X 7 d).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with mechanical ventilation, VAP occurred significantly later with thymosin than with routine therapy.

    In plain wordsIn ventilated patients, pneumonia started later with thymosin alpha‑1 than with routine care.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseOccurrence time of VAP
    Study

    n = 52

    Comparator
    Routine therapy
    Outcome group
    Infection and antimicrobial activity · Respiratory
    Studied dose
    1.6 mg once daily · subcutaneous injection · 7 daysAs given in this study (human).

    Source sentences

    Summary
    The occurrence time of VAP in thymosin therapy group was significantly later than that in routine therapy group (P<0.05).
    2 context sentences
    Summary · context
    Fifty two patients with expectancy of mechanical ventilation over 48 h were divided into routine therapy group (n=26) and thymosin therapy group (n= 26) in random.
    Summary · context
    The patients in routine therapy group were given intensive care unit (ICU) conventional treatment, and the patients in thymosin therapy group were given thymosin treatment additionally (1.6 mg subcutaneous injection, qd X 7 d).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with mechanical ventilation, the duration of machine ventilation was shorter with thymosin than with routine therapy.

    In plain wordsIn ventilated patients, time on the ventilator was shorter with thymosin alpha‑1 than with routine care.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseDuration of mechanical ventilation
    Study

    n = 52

    Comparator
    Routine therapy
    Outcome group
    Respiratory function · Respiratory
    Studied dose
    1.6 mg once daily · subcutaneous injection · 7 daysAs given in this study (human).

    Source sentences

    Summary
    The durations of machine ventilation and ICU stay in thymosin therapy group were shorter than those in routine therapy group (P<0.05).
    2 context sentences
    Summary · context
    Fifty two patients with expectancy of mechanical ventilation over 48 h were divided into routine therapy group (n=26) and thymosin therapy group (n= 26) in random.
    Summary · context
    The patients in routine therapy group were given intensive care unit (ICU) conventional treatment, and the patients in thymosin therapy group were given thymosin treatment additionally (1.6 mg subcutaneous injection, qd X 7 d).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In patients with mechanical ventilation, ICU stay was shorter with thymosin than with routine therapy.

    In plain wordsIn ventilated patients, ICU stay was shorter with thymosin alpha‑1 than with routine care.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseICU stay
    Study

    n = 52

    Comparator
    Routine therapy
    Outcome group
    Intensive care and hospital outcomes · Whole body
    Studied dose
    1.6 mg once daily · subcutaneous injection · 7 daysAs given in this study (human).

    Source sentences

    Summary
    The durations of machine ventilation and ICU stay in thymosin therapy group were shorter than those in routine therapy group (P<0.05).
    2 context sentences
    Summary · context
    Fifty two patients with expectancy of mechanical ventilation over 48 h were divided into routine therapy group (n=26) and thymosin therapy group (n= 26) in random.
    Summary · context
    The patients in routine therapy group were given intensive care unit (ICU) conventional treatment, and the patients in thymosin therapy group were given thymosin treatment additionally (1.6 mg subcutaneous injection, qd X 7 d).
  5. 05HumanRandomized controlled trialEfficacy outcome

    In patients with mechanical ventilation, thymosin gave higher CD3+ T lymphocyte levels than routine therapy at day 3 and day 7.

    In plain wordsIn ventilated patients, thymosin alpha‑1 gave higher CD3+ T cell levels than routine care.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCD3+ T lymphocyte level at day 3 and day 7
    Study

    n = 52

    Comparator
    Routine therapy
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    1.6 mg once daily · subcutaneous injection · 7 daysAs given in this study (human).

    Source sentences

    Summary
    At the 3rd and 7th d after mechanical ventilation, thymosin therapy group achived higher levels of CD3+, CD4+, CD4+ /CD8+ T lymphocyte and CD14+ HLA-DR than routine therapy group did (P<0.05).
    2 context sentences
    Summary · context
    Fifty two patients with expectancy of mechanical ventilation over 48 h were divided into routine therapy group (n=26) and thymosin therapy group (n= 26) in random.
    Summary · context
    The patients in routine therapy group were given intensive care unit (ICU) conventional treatment, and the patients in thymosin therapy group were given thymosin treatment additionally (1.6 mg subcutaneous injection, qd X 7 d).
  6. 06HumanRandomized controlled trialEfficacy outcome

    In patients with mechanical ventilation, thymosin gave higher CD4+ T lymphocyte levels than routine therapy at day 3 and day 7.

    In plain wordsIn ventilated patients, thymosin alpha‑1 gave higher CD4+ T cell levels than routine care.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCD4+ T lymphocyte level at day 3 and day 7
    Study

    n = 52

    Comparator
    Routine therapy
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    1.6 mg once daily · subcutaneous injection · 7 daysAs given in this study (human).

    Source sentences

    Summary
    At the 3rd and 7th d after mechanical ventilation, thymosin therapy group achived higher levels of CD3+, CD4+, CD4+ /CD8+ T lymphocyte and CD14+ HLA-DR than routine therapy group did (P<0.05).
    2 context sentences
    Summary · context
    Fifty two patients with expectancy of mechanical ventilation over 48 h were divided into routine therapy group (n=26) and thymosin therapy group (n= 26) in random.
    Summary · context
    The patients in routine therapy group were given intensive care unit (ICU) conventional treatment, and the patients in thymosin therapy group were given thymosin treatment additionally (1.6 mg subcutaneous injection, qd X 7 d).
  7. 07HumanRandomized controlled trialEfficacy outcome

    In patients with mechanical ventilation, thymosin gave a higher CD4+/CD8+ ratio than routine therapy at day 3 and day 7.

    In plain wordsIn ventilated patients, thymosin alpha‑1 gave a higher CD4+/CD8+ T cell ratio than routine care.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCD4+/CD8+ ratio at day 3 and day 7
    Study

    n = 52

    Comparator
    Routine therapy
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    1.6 mg once daily · subcutaneous injection · 7 daysAs given in this study (human).

    Source sentences

    Summary
    At the 3rd and 7th d after mechanical ventilation, thymosin therapy group achived higher levels of CD3+, CD4+, CD4+ /CD8+ T lymphocyte and CD14+ HLA-DR than routine therapy group did (P<0.05).
    2 context sentences
    Summary · context
    Fifty two patients with expectancy of mechanical ventilation over 48 h were divided into routine therapy group (n=26) and thymosin therapy group (n= 26) in random.
    Summary · context
    The patients in routine therapy group were given intensive care unit (ICU) conventional treatment, and the patients in thymosin therapy group were given thymosin treatment additionally (1.6 mg subcutaneous injection, qd X 7 d).
  8. 08HumanRandomized controlled trialEfficacy outcome

    In patients with mechanical ventilation, thymosin gave higher CD14+ HLA-DR levels than routine therapy at day 3 and day 7.

    In plain wordsIn ventilated patients, thymosin alpha‑1 gave higher levels of an immune cell marker than routine care.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCD14+ HLA-DR level at day 3 and day 7
    Study

    n = 52

    Comparator
    Routine therapy
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    1.6 mg once daily · subcutaneous injection · 7 daysAs given in this study (human).

    Source sentences

    Summary
    At the 3rd and 7th d after mechanical ventilation, thymosin therapy group achived higher levels of CD3+, CD4+, CD4+ /CD8+ T lymphocyte and CD14+ HLA-DR than routine therapy group did (P<0.05).
    2 context sentences
    Summary · context
    Fifty two patients with expectancy of mechanical ventilation over 48 h were divided into routine therapy group (n=26) and thymosin therapy group (n= 26) in random.
    Summary · context
    The patients in routine therapy group were given intensive care unit (ICU) conventional treatment, and the patients in thymosin therapy group were given thymosin treatment additionally (1.6 mg subcutaneous injection, qd X 7 d).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 17:28 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.